NEW RESULTS IN VIRAL CLEARANCE 1
CLINICAL TRIAL
2
NCT 04199078
RANDOMISED, MULTICENTRE, PROSPECTIVE, OPEN LABEL, CONTROLLED CLINICAL TRIAL WITH ROUTINE CLINICAL PRACTICE AT 6 MONTHS
HR-HPV (16-18-31)
HR-HPV
Papilocare® group
Papilocare® group
N=1 2 4
DON'T WAIT 24 MONTHS. TAKE ACTION NOW.
Clearance at 6 months in HPV 16,18 and 31 population
Clearance at 6 months in HR-HPV population
**
100 90 80 70 60 50 40 30 20 10 0
100 90 80 70 60 50 40 30 20 10 0
**
93.3%
88.5%
46.4%
30.8%
Control
Papilocare® Intensive regimen
p=0.0011
p=0.0011
Control
Papilocare® Intensive regimen
Control
Papilocare® Intensive Regimen: 3 months 1 cannula per day + 3 months 1 cannula every other day
1. Riera M; Fiol G; Valenzuela O ; Centeno C; Lopez B; Coll M.E cacy of a multi-ingredient Coriolus versicolor-based vaginal gel on High-risk HPV Clearance: Preliminary results from the Paloma 2 Clinical Trial [Poster Viewing #1919] International Papillomavirus Conference (IPVC). Edinburgh 2024
Made with FlippingBook - Online magazine maker